Clinical Trials · NCT02963922
Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 396
- Start date
- Feb 2017
- Locations
- 54 sites, 7 countries
- Primary endpoint
- Change in Body Weight (%)